John Stahl
Partner, US Pricing and Market Access
John Stahl is a Partner with Clarivate’s Commercial Strategy Consulting team and leads the US Pricing and Market Access practice.
John leverages over 20 years of deep healthcare knowledge as well as a broad range of market access and commercialization experience to effectively deliver strategic and actionable insights to biopharmaceutical and medtech clients. John has been with Clarivate for 10+ years, and during this time, he has supported clients with the development of market access landscape assessments, evidence generation and value communication strategies, pricing and contracting strategies, and account engagement strategies and tactics. His experience spans numerous TAs, with a concentration in cell and gene therapy, rare disease, oncology, immunology, and neurology conditions.
Prior to joining Clarivate, John spent over ten years in the pharmaceutical industry working for Johnson & Johnson and Novartis, in a variety of positions of increasing responsibility, including business analytics, business development, sales, marketing, and managed markets.
John graduated from Duke University with a B.A. in Economics and a B.A. in German. He also completed the Certificate program in Markets and Management Studies.
Latest news
Clarivate’s IPfolio and Renewal Services Selected by IGT
Managing global intellectual property more efficiently with trusted data, expert support and integrated services London, U.K. May 21, 2026: Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today…
Clarivate Selected By Czech National Library of Technology to Develop Unified National Library Platform
New cloud-based, shared platform based on Alma and Primo to help National Library of Technology advance library services and information accessibility London, U.K. May 19, 2026: Clarivate Plc (NYSE:CLVT), a…
Clarivate Identifies Five Medtech Trends Set to Redefine Growth Opportunities in 2026
New Medtech Trends to Watch report highlights market shifts, care delivery changes and competitive dynamics poised to reshape medtech strategy London, U.K. May 13, 2026. Clarivate Plc (NYSE:CLVT), a leading…